Costs and consequences of different chemotherapy regimens in metastatic colorectal cancer.
An economic sub-study was run alongside a large multi-centre randomised trial (MRC-CR06) comparing three chemotherapy regimens; de Gramont, Lokich and raltitrexed in patients with metastatic colorectal cancer. Patients in six of 45 centres in the main trial were approached to take part in the sub-st...
Main Authors: | Hale, J, Cohen, DR, Maughan, T, Stephens, R |
---|---|
Format: | Journal article |
Language: | English |
Published: |
2002
|
Similar Items
-
Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial.
by: Maughan, T, et al.
Published: (2002) -
Cetuximab plus Irinotecan as third line chemotherapy for metastatic colorectal cancer
by: Moe, M, et al.
Published: (2008) -
Chemotherapy-free intervals for patients with metastatic colorectal cancer remain an option.
by: Maughan, T, et al.
Published: (2010) -
Cetuximab therapy in first-line metastatic colorectal cancer and intermittent palliative chemotherapy: review of the COIN trial.
by: Adams, R, et al.
Published: (2008) -
Chemotherapy for colorectal cancer in the metastatic and adjuvant setting: past, present and future.
by: Sabharwal, A, et al.
Published: (2007)